Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 1

Conditions

Stomach Neoplasms 43Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 17Colorectal Neoplasms 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Sarcoma 11Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Triple Negative Breast Neoplasms 10Lung Neoplasms 10Cholangiocarcinoma 10Esophageal Squamous Cell Carcinoma 9Esophageal Neoplasms 9Osteosarcoma 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Neoplasms 6Head and Neck Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Liver Neoplasms 5Glioma 5Drug-Related Side Effects and Adverse Reactions 4Thyroid Neoplasms 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × apatinib × Clear all
NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Ruijin Hospital

Phase 2 Active not recruiting
80 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT03407976 2020-07-15

APPEASE

University of Utah

Phase 1 Terminated
5 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡